在关键试验中,Dupixent提高了血压缓解率的5倍,这可能导致监管部门批准. Dupixent improves BP remission rate fivefold in pivotal trial, potentially leading to regulatory approval.

在对严重皮肤疾病 - - 球状皮虫 (BP) 的关键试验中,Dupixent (dupilumab) 显示出显著的疗效. Dupixent (dupilumab) has shown remarkable efficacy in a pivotal trial for bullous pemphigoid (BP), a serious skin disease. 在ADEPT研究中,与安慰剂组相比,接受Dupixent的患者获得持续疾病缓解的可能性是服用该药的5倍. In the ADEPT study, patients receiving Dupixent were five times more likely to achieve sustained disease remission compared to those on placebo. 这种治疗的成功可能会导致美国和欧洲的监管部门批准, 为血压管理提供新的选择, 并可能减少对类固醇的依赖. This treatment's success may lead to regulatory approvals in the U.S. and Europe, offering a new option for BP management and potentially reducing reliance on steroids.